Norgine Ltd.

Commencement of brand naming marks a significant milestone in the development of a brand identity for the market-leading CD8 ImmunoPET technology ImaginAb Inc, a market-leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radiopharmaceutical therapy (RPT), today announced it will be partnering with Miami-based branding agency, Brand Institute, on the development of a global brand name for ImaginAb’s CD8 ImmunoPET technology. This follows the recent notification from the American Medical Association that the USAN Council has adopted the non-proprietary name crefmirlimab for the minibody, what was previously known as IAB22MC. As a result, ImaginAb’s CD8 ImmunoPET technology is now known as 89Zr-Df-crefmirlimab. Development of 89Zr-Df-crefmirlimab’s brand name is the next and final naming milestone in the development of this new and exciting technology. Radiopharmaceutical imaging agent brand name development is a uniquely challenging endeavor, typically requiring the support of a naming agency that specializes in the discipline. Commenting on the announcement, Ian Wilson, President & Chief Executive Officer of ImaginAb stated: “We are delighted to announce our partnership with Brand Institute, the global leader in pharmaceutical and healthcare-related brand name development. Brand Institute has a decades-long track record of developing blockbuster pharmaceutical brand names, and their team of regulatory experts is unmatched in the industry.” ImaginAb CD8 ImmunoPET technology is currently in phase II clinical trials and is used by a number of the leading pharmaceutical and biotech companies within their own pre-clinical and clinical trials through a number of non-exclusive commercial partnerships. “Brand Institute is grateful for the opportunity to partner with ImaginAb on the development of a brand name and identity for 89Zr-Df-crefmirlimab,” said James L. Dettore, Brand Institute’s Chairman & Chief Executive Officer. “We are excited to work alongside this truly disruptive company that is reimagining radiopharmaceutical imaging and the potential it has for improving treatment outcomes for immune oncology patients.” The final brand name will be subject to FDA and alternative global health authority approval. About ImaginAb ImaginAb Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineer antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET Imaging technology and therapeutic isotopes, these novel minibodies bind specifically to cell surface targets, providing physicians with a whole-body picture of immune activity and the potential to treat cancer. ImaginAb is advancing a pipeline of Minibodies against both oncology and immunology targets. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, TRC, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. About CD8 ImmunoPET The 89Zr CD8 Immuno-PET agent (89Zr-Df-IAB22M2C) is a 89Zr-labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8 T cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes. For further information please contact: Preeti Chana Marketing & Communications Manager, ImaginAb pchana@imaginab.com

LOS ANGELES, CA, USA I May 18, 2023 I ImaginAb, Inc., a global biotechnology company focused on the development of radiopharmaceuticals for the diagnosis and treatment of cancer, today announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors. In parallel, the DLL3 targeting program, IAB57, will further assess several leads in the coming quarter prior to initiation of IND-enabling studies later in 2023. ImaginAb's discovery team developed IAB56 and IAB57 at its Los Angeles R&D site via screening and selection of high affinity minibodies and cys-dibodies with demonstrated therapeutic efficacy in preclinical models. The αvβ6 integrin is a pan-cancer antigen implicated in a broad range of solid tumors including ovarian, pancreatic, breast, oral and liver cancer amongst others. The target shows expression which is highly specific to malignant diseases with very little or no expression in healthy tissues, making it an attractive candidate for targeted radiotherapy of solid cancers. Delta-like ligand 3 (DLL3) is highly selective for SCLC and neuroendocrine tumors, with minimal to no expression in healthy tissues. Given the rapid recurrence of SCLC following existing therapeutic option, there remains a significant need to improve prognosis for patients suffering from this disease. Ian Wilson, Chief Executive Officer of ImaginAb, said: "The ImaginAb team has experience in the discovery, development, and manufacture of radiopharmaceuticals. Focusing our discovery team on the identification and progression of new radiopharmaceutical therapy agents based on our proprietary platform of biologics was a natural step for ImaginAb. We are excited to announce these new developments and look forward to sharing news on these and other candidate molecules as new milestones are met." About ImaginAb ImaginAb, Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapeutic agents. ImaginAb engineer's antibody fragments called minibodies and cys-diabodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert. ImaginAb is advancing a pipeline of minibodies against both oncology and immunology targets. The Company is backed by top tier venture capital firms and strategic corporate firms including Adage Capital Partners, the Cycad Group, Norgine Ventures, Innoviva, Jim Pallotta of the Raptor Group, the Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. ImaginAb's vision is to transform patient care, and help people live better and healthier lives. For more information visit www.imaginab.com . SOURCE: ImaginAb

IAB56 RPT agent is designed to target integrin αvβ6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies. IAB57 RPT agent is designed to target DLL3, a target over-expressed in cancer tissues and relevant in several cancers, most notably Small-Cell Lung Cancer (SCLC) LOS ANGELES, May 18, 2023 /PRNewswire/ -- ImaginAb, Inc., a global biotechnology company focused on the development of radiopharmaceuticals for the diagnosis and treatment of cancer, today announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors. In parallel, the DLL3 targeting program, IAB57, will further assess several leads in the coming quarter prior to initiation of IND-enabling studies later in 2023. ImaginAb's discovery team developed IAB56 and IAB57 at its Los Angeles R&D site via screening and selection of high affinity minibodies and cys-dibodies with demonstrated therapeutic efficacy in preclinical models. The αvβ6 integrin is a pan-cancer antigen implicated in a broad range of solid tumors including ovarian, pancreatic, breast, oral and liver cancer amongst others. The target shows expression which is highly specific to malignant diseases with very little or no expression in healthy tissues, making it an attractive candidate for targeted radiotherapy of solid cancers. Delta-like ligand 3 (DLL3) is highly selective for SCLC and neuroendocrine tumors, with minimal to no expression in healthy tissues. Given the rapid recurrence of SCLC following existing therapeutic option, there remains a significant need to improve prognosis for patients suffering from this disease. Ian Wilson, Chief Executive Officer of ImaginAb, said: "The ImaginAb team has experience in the discovery, development, and manufacture of radiopharmaceuticals. Focusing our discovery team on the identification and progression of new radiopharmaceutical therapy agents based on our proprietary platform of biologics was a natural step for ImaginAb. We are excited to announce these new developments and look forward to sharing news on these and other candidate molecules as new milestones are met." About ImaginAb ImaginAb, Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapeutic agents. ImaginAb engineer's antibody fragments called minibodies and cys-diabodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert. ImaginAb is advancing a pipeline of minibodies against both oncology and immunology targets. The Company is backed by top tier venture capital firms and strategic corporate firms including Adage Capital Partners, the Cycad Group, Norgine Ventures, Innoviva, Jim Pallotta of the Raptor Group, the Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. ImaginAb's vision is to transform patient care, and help people live better and healthier lives. For more information visit . Logo - SOURCE ImaginAb, Inc.